 Jon Matsumura
Concepts (437)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Vessel Prosthesis Implantation | 75 | 2023 | 181 | 13.910 |
Why?
| | Aortic Aneurysm, Abdominal | 58 | 2023 | 115 | 10.320 |
Why?
| | Endovascular Procedures | 38 | 2023 | 270 | 8.560 |
Why?
| | Blood Vessel Prosthesis | 49 | 2022 | 114 | 8.560 |
Why?
| | Aortic Aneurysm, Thoracic | 29 | 2022 | 117 | 7.540 |
Why?
| | Stents | 58 | 2023 | 475 | 7.400 |
Why?
| | Aorta, Thoracic | 24 | 2022 | 246 | 4.630 |
Why?
| | Carotid Stenosis | 21 | 2023 | 78 | 3.740 |
Why?
| | Vascular Surgical Procedures | 19 | 2018 | 262 | 2.840 |
Why?
| | Iliac Aneurysm | 7 | 2023 | 17 | 2.570 |
Why?
| | Tomography, X-Ray Computed | 32 | 2021 | 2404 | 2.230 |
Why?
| | Vascular System Injuries | 5 | 2018 | 64 | 2.180 |
Why?
| | Endarterectomy, Carotid | 12 | 2021 | 41 | 2.090 |
Why?
| | Prosthesis Design | 31 | 2022 | 288 | 2.070 |
Why?
| | Aortography | 15 | 2023 | 49 | 2.070 |
Why?
| | Aortic Diseases | 8 | 2019 | 95 | 1.960 |
Why?
| | Treatment Outcome | 81 | 2023 | 9164 | 1.920 |
Why?
| | Angioplasty | 10 | 2017 | 40 | 1.800 |
Why?
| | Iliac Artery | 9 | 2023 | 44 | 1.780 |
Why?
| | Aortic Rupture | 12 | 2022 | 25 | 1.690 |
Why?
| | Stroke | 16 | 2023 | 1016 | 1.580 |
Why?
| | Angioplasty, Balloon | 9 | 2013 | 90 | 1.540 |
Why?
| | Aortic Aneurysm | 8 | 2022 | 51 | 1.530 |
Why?
| | Time Factors | 44 | 2023 | 6182 | 1.410 |
Why?
| | Aged | 86 | 2023 | 19296 | 1.270 |
Why?
| | Aged, 80 and over | 44 | 2023 | 6434 | 1.260 |
Why?
| | Sarcopenia | 2 | 2019 | 66 | 1.210 |
Why?
| | Computed Tomography Angiography | 6 | 2023 | 105 | 1.110 |
Why?
| | Prosthesis Failure | 10 | 2017 | 116 | 1.060 |
Why?
| | Postoperative Complications | 28 | 2022 | 2164 | 1.020 |
Why?
| | Subclavian Artery | 6 | 2022 | 29 | 1.010 |
Why?
| | Vascular Patency | 12 | 2021 | 97 | 0.970 |
Why?
| | Humans | 158 | 2023 | 115879 | 0.930 |
Why?
| | Middle Aged | 65 | 2023 | 27085 | 0.910 |
Why?
| | Risk Factors | 32 | 2023 | 8715 | 0.890 |
Why?
| | Myocardial Infarction | 3 | 2021 | 932 | 0.870 |
Why?
| | Male | 101 | 2023 | 56117 | 0.860 |
Why?
| | Femoral Artery | 4 | 2013 | 168 | 0.840 |
Why?
| | Vena Cava Filters | 5 | 2023 | 50 | 0.840 |
Why?
| | Prospective Studies | 29 | 2023 | 6279 | 0.820 |
Why?
| | Aorta, Abdominal | 7 | 2020 | 39 | 0.800 |
Why?
| | Ulcer | 3 | 2014 | 28 | 0.780 |
Why?
| | Female | 96 | 2023 | 60082 | 0.780 |
Why?
| | Foreign-Body Migration | 3 | 2017 | 38 | 0.710 |
Why?
| | Risk Assessment | 18 | 2023 | 2992 | 0.700 |
Why?
| | United States | 31 | 2022 | 12322 | 0.700 |
Why?
| | Ischemia | 5 | 2018 | 363 | 0.690 |
Why?
| | Peripheral Arterial Disease | 2 | 2018 | 379 | 0.690 |
Why?
| | Frailty | 2 | 2019 | 116 | 0.680 |
Why?
| | Retrospective Studies | 41 | 2023 | 12616 | 0.670 |
Why?
| | Predictive Value of Tests | 9 | 2021 | 1814 | 0.670 |
Why?
| | Reoperation | 12 | 2020 | 525 | 0.660 |
Why?
| | Psoas Muscles | 1 | 2018 | 5 | 0.660 |
Why?
| | Popliteal Artery | 4 | 2015 | 59 | 0.650 |
Why?
| | Marfan Syndrome | 1 | 2019 | 42 | 0.650 |
Why?
| | Body Composition | 2 | 2019 | 579 | 0.630 |
Why?
| | Population Surveillance | 1 | 2021 | 395 | 0.610 |
Why?
| | Societies, Medical | 5 | 2020 | 685 | 0.610 |
Why?
| | Endoleak | 7 | 2022 | 13 | 0.590 |
Why?
| | Chlorhexidine | 1 | 2017 | 22 | 0.570 |
Why?
| | Decontamination | 1 | 2017 | 23 | 0.570 |
Why?
| | Elective Surgical Procedures | 8 | 2020 | 154 | 0.560 |
Why?
| | Anti-Infective Agents, Local | 1 | 2017 | 40 | 0.560 |
Why?
| | Health Care Costs | 3 | 2014 | 384 | 0.550 |
Why?
| | Embolization, Therapeutic | 2 | 2022 | 181 | 0.530 |
Why?
| | Doxycycline | 3 | 2023 | 56 | 0.530 |
Why?
| | Infection Control | 1 | 2017 | 137 | 0.520 |
Why?
| | Radiography, Interventional | 5 | 2019 | 111 | 0.510 |
Why?
| | Education, Medical, Continuing | 2 | 2014 | 119 | 0.490 |
Why?
| | Patient Readmission | 3 | 2014 | 609 | 0.480 |
Why?
| | Lower Extremity | 1 | 2018 | 338 | 0.480 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 251 | 0.470 |
Why?
| | Program Development | 2 | 2014 | 350 | 0.460 |
Why?
| | Alloys | 2 | 2013 | 31 | 0.450 |
Why?
| | Follow-Up Studies | 24 | 2020 | 4444 | 0.450 |
Why?
| | Vascular Diseases | 2 | 2014 | 230 | 0.440 |
Why?
| | Thoracic Injuries | 2 | 2013 | 54 | 0.440 |
Why?
| | Kaplan-Meier Estimate | 10 | 2019 | 816 | 0.440 |
Why?
| | Health Expenditures | 1 | 2014 | 173 | 0.430 |
Why?
| | Carotid Artery Diseases | 3 | 2005 | 58 | 0.420 |
Why?
| | Congresses as Topic | 1 | 2014 | 204 | 0.420 |
Why?
| | Skin | 1 | 2017 | 668 | 0.420 |
Why?
| | Patient Selection | 7 | 2021 | 655 | 0.410 |
Why?
| | Embolic Protection Devices | 1 | 2012 | 11 | 0.400 |
Why?
| | Constriction, Pathologic | 7 | 2023 | 210 | 0.390 |
Why?
| | Minimally Invasive Surgical Procedures | 7 | 2009 | 154 | 0.390 |
Why?
| | Pulmonary Embolism | 2 | 2005 | 182 | 0.380 |
Why?
| | Thromboembolism | 1 | 2012 | 93 | 0.380 |
Why?
| | Arterial Occlusive Diseases | 3 | 2008 | 73 | 0.370 |
Why?
| | Disease Progression | 6 | 2023 | 2423 | 0.370 |
Why?
| | Ultrasonography, Interventional | 3 | 2001 | 132 | 0.370 |
Why?
| | Intracranial Embolism | 1 | 2010 | 29 | 0.360 |
Why?
| | Muscle, Skeletal | 1 | 2019 | 1459 | 0.360 |
Why?
| | Wounds, Nonpenetrating | 5 | 2021 | 228 | 0.350 |
Why?
| | Filtration | 1 | 2010 | 62 | 0.350 |
Why?
| | Adult | 34 | 2022 | 30822 | 0.350 |
Why?
| | Peripheral Vascular Diseases | 2 | 2004 | 98 | 0.350 |
Why?
| | Chi-Square Distribution | 5 | 2014 | 501 | 0.320 |
Why?
| | Radiography | 7 | 2012 | 826 | 0.320 |
Why?
| | Thrombosis | 4 | 2018 | 302 | 0.320 |
Why?
| | Survival Rate | 10 | 2016 | 1650 | 0.320 |
Why?
| | Regional Blood Flow | 4 | 2018 | 414 | 0.310 |
Why?
| | Ultrasonography, Doppler, Duplex | 9 | 2017 | 39 | 0.310 |
Why?
| | Iliac Vein | 2 | 2006 | 9 | 0.310 |
Why?
| | Venous Thrombosis | 4 | 2005 | 147 | 0.300 |
Why?
| | Paraparesis | 2 | 2008 | 6 | 0.290 |
Why?
| | Spinal Cord Ischemia | 2 | 2010 | 63 | 0.280 |
Why?
| | Graft Occlusion, Vascular | 4 | 2018 | 35 | 0.280 |
Why?
| | Hospitals, University | 1 | 2007 | 172 | 0.280 |
Why?
| | Hospital Mortality | 4 | 2020 | 779 | 0.270 |
Why?
| | Health Status | 3 | 2019 | 728 | 0.260 |
Why?
| | Ankle Brachial Index | 2 | 2018 | 30 | 0.260 |
Why?
| | Epidemiologic Research Design | 1 | 2005 | 27 | 0.260 |
Why?
| | Clinical Trials as Topic | 4 | 2019 | 944 | 0.240 |
Why?
| | Retreatment | 2 | 2021 | 70 | 0.240 |
Why?
| | Erectile Dysfunction | 2 | 2023 | 38 | 0.240 |
Why?
| | Length of Stay | 5 | 2020 | 960 | 0.240 |
Why?
| | Severity of Illness Index | 8 | 2017 | 2590 | 0.230 |
Why?
| | Multicenter Studies as Topic | 3 | 2014 | 249 | 0.230 |
Why?
| | Preoperative Care | 3 | 2017 | 318 | 0.230 |
Why?
| | Femoral Vein | 3 | 2001 | 28 | 0.230 |
Why?
| | Matrix Metalloproteinase 3 | 1 | 2023 | 23 | 0.220 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2023 | 118 | 0.210 |
Why?
| | Comorbidity | 7 | 2019 | 1476 | 0.210 |
Why?
| | Feasibility Studies | 7 | 2022 | 750 | 0.210 |
Why?
| | Catheterization, Peripheral | 3 | 2009 | 105 | 0.210 |
Why?
| | Paraplegia | 4 | 2011 | 52 | 0.210 |
Why?
| | Carotid Artery, Internal | 5 | 2008 | 33 | 0.210 |
Why?
| | Double-Blind Method | 3 | 2023 | 1664 | 0.210 |
Why?
| | Prosthesis Implantation | 2 | 2002 | 139 | 0.200 |
Why?
| | Aftercare | 2 | 2020 | 187 | 0.200 |
Why?
| | Vascular Calcification | 1 | 2023 | 108 | 0.200 |
Why?
| | Clinical Competence | 6 | 2019 | 924 | 0.190 |
Why?
| | Registries | 2 | 2019 | 1772 | 0.190 |
Why?
| | Odds Ratio | 3 | 2014 | 968 | 0.190 |
Why?
| | Reproducibility of Results | 3 | 2018 | 2807 | 0.190 |
Why?
| | Equipment Design | 5 | 2011 | 518 | 0.190 |
Why?
| | Logistic Models | 4 | 2015 | 1863 | 0.190 |
Why?
| | Patients' Rooms | 1 | 2000 | 13 | 0.190 |
Why?
| | Eligibility Determination | 1 | 2021 | 60 | 0.180 |
Why?
| | Collateral Circulation | 2 | 2010 | 19 | 0.180 |
Why?
| | Cause of Death | 4 | 2019 | 368 | 0.180 |
Why?
| | Abdominal Oblique Muscles | 1 | 2019 | 1 | 0.180 |
Why?
| | Intercostal Muscles | 1 | 2019 | 3 | 0.180 |
Why?
| | Thoracic Outlet Syndrome | 2 | 1997 | 12 | 0.180 |
Why?
| | Rectus Abdominis | 1 | 2019 | 9 | 0.170 |
Why?
| | Superficial Back Muscles | 1 | 2019 | 13 | 0.170 |
Why?
| | Spinal Fusion | 1 | 2022 | 216 | 0.170 |
Why?
| | Oleic Acids | 1 | 1999 | 10 | 0.170 |
Why?
| | Credentialing | 1 | 2019 | 12 | 0.170 |
Why?
| | Cost-Benefit Analysis | 2 | 2020 | 548 | 0.170 |
Why?
| | Specialties, Surgical | 1 | 2020 | 71 | 0.170 |
Why?
| | Aneurysm, Ruptured | 2 | 2013 | 34 | 0.160 |
Why?
| | Curriculum | 1 | 2005 | 856 | 0.160 |
Why?
| | Anti-Bacterial Agents | 2 | 2020 | 1486 | 0.160 |
Why?
| | Observer Variation | 2 | 2018 | 298 | 0.160 |
Why?
| | Frail Elderly | 1 | 2019 | 105 | 0.160 |
Why?
| | Surgeons | 1 | 2022 | 238 | 0.160 |
Why?
| | Phosphatidylcholines | 1 | 1999 | 134 | 0.160 |
Why?
| | Disease-Free Survival | 3 | 2017 | 621 | 0.160 |
Why?
| | Gene Transfer Techniques | 1 | 1999 | 149 | 0.160 |
Why?
| | Electronic Mail | 1 | 2018 | 54 | 0.160 |
Why?
| | Protease Inhibitors | 1 | 2019 | 102 | 0.150 |
Why?
| | Critical Illness | 3 | 2018 | 648 | 0.150 |
Why?
| | Neck Muscles | 1 | 1997 | 11 | 0.150 |
Why?
| | Limb Salvage | 1 | 2018 | 52 | 0.150 |
Why?
| | Ribs | 1 | 1997 | 30 | 0.150 |
Why?
| | Anatomic Landmarks | 1 | 2017 | 23 | 0.150 |
Why?
| | Clavicle | 1 | 1997 | 31 | 0.150 |
Why?
| | Blood Vessels | 1 | 1999 | 181 | 0.140 |
Why?
| | Administration, Cutaneous | 1 | 2017 | 116 | 0.140 |
Why?
| | Axillary Artery | 1 | 1996 | 12 | 0.140 |
Why?
| | Bile Pigments | 1 | 1996 | 1 | 0.140 |
Why?
| | Incidence | 7 | 2016 | 2336 | 0.140 |
Why?
| | Bile | 1 | 1996 | 26 | 0.130 |
Why?
| | Cholagogues and Choleretics | 1 | 1996 | 9 | 0.130 |
Why?
| | Quality Assurance, Health Care | 2 | 2019 | 315 | 0.130 |
Why?
| | Cholelithiasis | 1 | 1996 | 31 | 0.130 |
Why?
| | Analysis of Variance | 2 | 2016 | 1227 | 0.130 |
Why?
| | United States Food and Drug Administration | 2 | 2009 | 173 | 0.130 |
Why?
| | Anti-Inflammatory Agents | 1 | 2019 | 447 | 0.130 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 432 | 0.130 |
Why?
| | Antioxidants | 1 | 2019 | 534 | 0.130 |
Why?
| | Survival Analysis | 6 | 2016 | 1218 | 0.120 |
Why?
| | Spinal Injuries | 1 | 1995 | 48 | 0.120 |
Why?
| | Chicago | 3 | 2011 | 45 | 0.120 |
Why?
| | Evidence-Based Medicine | 4 | 2017 | 685 | 0.120 |
Why?
| | Prosthesis-Related Infections | 2 | 2008 | 70 | 0.120 |
Why?
| | Hypertension | 2 | 2021 | 1065 | 0.120 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 467 | 0.120 |
Why?
| | Intermittent Claudication | 1 | 2015 | 108 | 0.120 |
Why?
| | Hospital Costs | 1 | 2014 | 105 | 0.110 |
Why?
| | Wisconsin | 1 | 2013 | 91 | 0.110 |
Why?
| | Asymptomatic Diseases | 3 | 2019 | 77 | 0.110 |
Why?
| | Clinical Decision-Making | 3 | 2021 | 273 | 0.110 |
Why?
| | Imaging, Three-Dimensional | 2 | 2016 | 495 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2021 | 905 | 0.110 |
Why?
| | Taurocholic Acid | 1 | 1993 | 34 | 0.110 |
Why?
| | Gastrointestinal Diseases | 1 | 1995 | 184 | 0.110 |
Why?
| | Parenteral Nutrition, Total | 1 | 1993 | 34 | 0.110 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 127 | 0.110 |
Why?
| | Endothelium, Vascular | 1 | 1999 | 845 | 0.110 |
Why?
| | Postoperative Care | 1 | 2014 | 222 | 0.110 |
Why?
| | Biomarkers | 1 | 2023 | 3474 | 0.110 |
Why?
| | Aneurysm | 2 | 2003 | 29 | 0.110 |
Why?
| | Intestinal Absorption | 1 | 1993 | 93 | 0.110 |
Why?
| | Communication | 1 | 2018 | 749 | 0.110 |
Why?
| | Ileum | 1 | 1993 | 93 | 0.110 |
Why?
| | Leg | 3 | 1999 | 227 | 0.110 |
Why?
| | Intraoperative Complications | 3 | 2019 | 126 | 0.100 |
Why?
| | Europe | 1 | 2013 | 343 | 0.100 |
Why?
| | Device Approval | 2 | 2009 | 21 | 0.100 |
Why?
| | Electronic Health Records | 1 | 2018 | 805 | 0.100 |
Why?
| | Permeability | 2 | 2009 | 151 | 0.100 |
Why?
| | Exercise Tolerance | 1 | 2013 | 223 | 0.100 |
Why?
| | Catheters | 1 | 2011 | 66 | 0.100 |
Why?
| | Residence Characteristics | 1 | 2013 | 276 | 0.100 |
Why?
| | Proportional Hazards Models | 3 | 2009 | 1088 | 0.100 |
Why?
| | Cardiovascular Diseases | 1 | 2022 | 1724 | 0.100 |
Why?
| | Viscera | 1 | 2011 | 13 | 0.100 |
Why?
| | Bayes Theorem | 2 | 2023 | 333 | 0.100 |
Why?
| | Netherlands | 2 | 2020 | 65 | 0.090 |
Why?
| | United States Department of Veterans Affairs | 1 | 2014 | 557 | 0.090 |
Why?
| | Ambulatory Care | 1 | 2014 | 479 | 0.090 |
Why?
| | Vertebrobasilar Insufficiency | 1 | 2010 | 7 | 0.090 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2417 | 0.090 |
Why?
| | Aneurysm, False | 1 | 2011 | 46 | 0.090 |
Why?
| | Anesthesiology | 1 | 1990 | 36 | 0.090 |
Why?
| | Research Design | 3 | 2009 | 949 | 0.090 |
Why?
| | Databases as Topic | 1 | 2010 | 63 | 0.090 |
Why?
| | Exercise Test | 1 | 2013 | 541 | 0.090 |
Why?
| | Telemedicine | 1 | 2018 | 667 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1443 | 0.090 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2009 | 27 | 0.090 |
Why?
| | Socioeconomic Factors | 1 | 2013 | 1088 | 0.090 |
Why?
| | Hospitals, Urban | 1 | 2010 | 129 | 0.090 |
Why?
| | Ischemic Attack, Transient | 2 | 2009 | 61 | 0.090 |
Why?
| | General Surgery | 2 | 2014 | 130 | 0.080 |
Why?
| | Dilatation, Pathologic | 2 | 1999 | 54 | 0.080 |
Why?
| | Porosity | 1 | 2009 | 93 | 0.080 |
Why?
| | Benchmarking | 1 | 2010 | 163 | 0.080 |
Why?
| | Extremities | 1 | 2009 | 113 | 0.080 |
Why?
| | Aorta | 2 | 2022 | 354 | 0.080 |
Why?
| | Age Factors | 2 | 2019 | 2911 | 0.080 |
Why?
| | Rupture | 1 | 2009 | 95 | 0.080 |
Why?
| | Carotid Arteries | 1 | 2010 | 183 | 0.080 |
Why?
| | Coronary Artery Bypass | 2 | 2000 | 196 | 0.080 |
Why?
| | Ultrasonography | 4 | 2014 | 669 | 0.080 |
Why?
| | Young Adult | 4 | 2021 | 10510 | 0.080 |
Why?
| | Treatment Failure | 2 | 2020 | 332 | 0.070 |
Why?
| | Patient Discharge | 1 | 2013 | 770 | 0.070 |
Why?
| | Carotid Artery Thrombosis | 1 | 2007 | 7 | 0.070 |
Why?
| | Organ Size | 2 | 2020 | 434 | 0.070 |
Why?
| | Equipment Safety | 2 | 2009 | 40 | 0.070 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2004 | 690 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2014 | 847 | 0.070 |
Why?
| | Brain Ischemia | 1 | 2010 | 298 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2004 | 0.070 |
Why?
| | Calcinosis | 1 | 2009 | 244 | 0.070 |
Why?
| | Arm | 2 | 1997 | 105 | 0.070 |
Why?
| | Stainless Steel | 1 | 2006 | 21 | 0.070 |
Why?
| | Angiography | 3 | 2017 | 177 | 0.070 |
Why?
| | Prostheses and Implants | 1 | 2007 | 141 | 0.070 |
Why?
| | Polyesters | 1 | 2006 | 65 | 0.070 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2005 | 58 | 0.060 |
Why?
| | Recurrence | 3 | 2017 | 950 | 0.060 |
Why?
| | Hematoma | 1 | 2005 | 51 | 0.060 |
Why?
| | Vena Cava, Inferior | 2 | 2023 | 55 | 0.060 |
Why?
| | Renal Veins | 1 | 2004 | 9 | 0.060 |
Why?
| | Mesenteric Artery, Superior | 1 | 2004 | 12 | 0.060 |
Why?
| | Health Status Indicators | 1 | 2005 | 155 | 0.060 |
Why?
| | United Kingdom | 2 | 2003 | 230 | 0.060 |
Why?
| | Hernia, Ventral | 1 | 2004 | 18 | 0.060 |
Why?
| | Leadership | 1 | 2007 | 303 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1217 | 0.060 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2023 | 13 | 0.060 |
Why?
| | Head and Neck Neoplasms | 1 | 2007 | 425 | 0.050 |
Why?
| | Nephrectomy | 1 | 2004 | 150 | 0.050 |
Why?
| | Fluoroscopy | 2 | 2001 | 141 | 0.050 |
Why?
| | Delphi Technique | 1 | 2023 | 164 | 0.050 |
Why?
| | Data Collection | 1 | 2006 | 637 | 0.050 |
Why?
| | Cerebrovascular Disorders | 2 | 2000 | 82 | 0.050 |
Why?
| | Perfusion | 1 | 2023 | 152 | 0.050 |
Why?
| | Animals | 4 | 2019 | 32162 | 0.050 |
Why?
| | Lumbosacral Region | 1 | 2022 | 46 | 0.050 |
Why?
| | Substance-Related Disorders | 1 | 1990 | 952 | 0.050 |
Why?
| | Quality of Health Care | 1 | 2007 | 577 | 0.050 |
Why?
| | Illinois | 3 | 2008 | 37 | 0.050 |
Why?
| | Learning Curve | 1 | 2022 | 65 | 0.050 |
Why?
| | Device Removal | 1 | 2023 | 128 | 0.050 |
Why?
| | Time | 1 | 2002 | 73 | 0.050 |
Why?
| | Arteries | 1 | 2023 | 250 | 0.050 |
Why?
| | England | 1 | 2001 | 63 | 0.050 |
Why?
| | Maxillary Sinus Neoplasms | 1 | 2001 | 7 | 0.050 |
Why?
| | Consensus | 1 | 2023 | 531 | 0.050 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 77 | 0.050 |
Why?
| | Biomedical Research | 1 | 2007 | 589 | 0.050 |
Why?
| | Internship and Residency | 1 | 1990 | 957 | 0.050 |
Why?
| | Costs and Cost Analysis | 1 | 2001 | 200 | 0.050 |
Why?
| | Peritoneum | 1 | 2000 | 36 | 0.050 |
Why?
| | Practice Guidelines as Topic | 4 | 2010 | 1405 | 0.050 |
Why?
| | Cerebral Angiography | 1 | 2000 | 111 | 0.050 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 180 | 0.050 |
Why?
| | Quality of Life | 4 | 2012 | 2390 | 0.040 |
Why?
| | Radiotherapy | 1 | 2001 | 177 | 0.040 |
Why?
| | Troponin T | 1 | 2000 | 49 | 0.040 |
Why?
| | Injury Severity Score | 2 | 2013 | 460 | 0.040 |
Why?
| | Intracranial Aneurysm | 1 | 2000 | 91 | 0.040 |
Why?
| | Cation Exchange Resins | 1 | 1999 | 7 | 0.040 |
Why?
| | Spermine | 1 | 1999 | 27 | 0.040 |
Why?
| | Point-of-Care Systems | 1 | 2001 | 150 | 0.040 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 1999 | 15 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 3 | 2019 | 1182 | 0.040 |
Why?
| | Monitoring, Intraoperative | 1 | 1999 | 39 | 0.040 |
Why?
| | Echocardiography, Transesophageal | 1 | 2000 | 90 | 0.040 |
Why?
| | Luciferases | 1 | 1999 | 141 | 0.040 |
Why?
| | Emergency Treatment | 1 | 2020 | 115 | 0.040 |
Why?
| | Veins | 1 | 1999 | 57 | 0.040 |
Why?
| | Genes, Reporter | 1 | 1999 | 260 | 0.040 |
Why?
| | Glycine | 1 | 1999 | 156 | 0.040 |
Why?
| | Postoperative Period | 1 | 1999 | 292 | 0.040 |
Why?
| | Drug Carriers | 1 | 1999 | 113 | 0.040 |
Why?
| | Plasmids | 1 | 1999 | 346 | 0.040 |
Why?
| | Myocardial Contraction | 1 | 2000 | 316 | 0.040 |
Why?
| | Arteriosclerosis | 1 | 1998 | 83 | 0.040 |
Why?
| | Radiography, Abdominal | 1 | 1998 | 33 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 734 | 0.040 |
Why?
| | Surgical Flaps | 1 | 1999 | 121 | 0.040 |
Why?
| | Subclavian Vein | 1 | 1997 | 19 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 1998 | 140 | 0.040 |
Why?
| | Multiple Trauma | 2 | 2010 | 91 | 0.040 |
Why?
| | Veterans | 1 | 2008 | 1233 | 0.040 |
Why?
| | Blood Proteins | 1 | 1999 | 238 | 0.040 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 1997 | 29 | 0.040 |
Why?
| | Intraoperative Care | 1 | 1997 | 36 | 0.040 |
Why?
| | Hemodynamics | 2 | 2000 | 969 | 0.040 |
Why?
| | Transfection | 1 | 1999 | 868 | 0.040 |
Why?
| | Retroperitoneal Neoplasms | 1 | 1997 | 22 | 0.040 |
Why?
| | Prognosis | 2 | 2015 | 3344 | 0.040 |
Why?
| | Acute Disease | 2 | 2011 | 917 | 0.040 |
Why?
| | Lipid Metabolism | 1 | 1999 | 449 | 0.030 |
Why?
| | Cholic Acids | 1 | 1996 | 17 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 1999 | 1244 | 0.030 |
Why?
| | Atherosclerosis | 1 | 2019 | 341 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2001 | 577 | 0.030 |
Why?
| | Wound Healing | 1 | 1998 | 262 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2001 | 863 | 0.030 |
Why?
| | Taurine | 1 | 1996 | 41 | 0.030 |
Why?
| | Lipids | 1 | 1999 | 589 | 0.030 |
Why?
| | Movement | 1 | 1997 | 246 | 0.030 |
Why?
| | Sarcoma | 1 | 1997 | 137 | 0.030 |
Why?
| | Contrast Media | 1 | 1998 | 365 | 0.030 |
Why?
| | Prevalence | 1 | 2001 | 2270 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1999 | 1871 | 0.030 |
Why?
| | Dogs | 1 | 1996 | 344 | 0.030 |
Why?
| | Databases, Factual | 1 | 2019 | 1137 | 0.030 |
Why?
| | Bile Acids and Salts | 1 | 1996 | 172 | 0.030 |
Why?
| | Myocardium | 1 | 2000 | 929 | 0.030 |
Why?
| | Mass Screening | 1 | 2001 | 1024 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 1998 | 292 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1999 | 1138 | 0.030 |
Why?
| | Gene Expression | 1 | 1999 | 1442 | 0.030 |
Why?
| | Cohort Studies | 3 | 2012 | 4960 | 0.030 |
Why?
| | Accidents, Traffic | 2 | 2005 | 170 | 0.030 |
Why?
| | Swine, Miniature | 1 | 1993 | 71 | 0.030 |
Why?
| | Blood Flow Velocity | 2 | 2005 | 324 | 0.030 |
Why?
| | Least-Squares Analysis | 1 | 2012 | 73 | 0.030 |
Why?
| | DNA | 1 | 1999 | 1357 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 4447 | 0.030 |
Why?
| | Random Allocation | 1 | 1993 | 337 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2014 | 3054 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 1993 | 374 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2012 | 103 | 0.030 |
Why?
| | Cells, Cultured | 1 | 1999 | 3914 | 0.020 |
Why?
| | Anticoagulants | 1 | 2016 | 549 | 0.020 |
Why?
| | Physician Impairment | 1 | 1990 | 6 | 0.020 |
Why?
| | Swine | 1 | 1993 | 705 | 0.020 |
Why?
| | Polytetrafluoroethylene | 2 | 2003 | 25 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 2003 | 3072 | 0.020 |
Why?
| | Infant | 1 | 2023 | 7992 | 0.020 |
Why?
| | Blood Component Transfusion | 1 | 2010 | 76 | 0.020 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2009 | 63 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2010 | 309 | 0.020 |
Why?
| | Probability | 1 | 2010 | 295 | 0.020 |
Why?
| | Medicare | 1 | 2014 | 666 | 0.020 |
Why?
| | Morbidity | 1 | 2009 | 278 | 0.020 |
Why?
| | Advisory Committees | 1 | 2009 | 208 | 0.020 |
Why?
| | Postoperative Hemorrhage | 1 | 2008 | 78 | 0.020 |
Why?
| | Suture Techniques | 1 | 2008 | 130 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 960 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 4675 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2010 | 497 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 1996 | 3587 | 0.020 |
Why?
| | Catheterization | 1 | 2007 | 160 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 2859 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2014 | 2201 | 0.020 |
Why?
| | Pyelonephritis, Xanthogranulomatous | 1 | 2004 | 1 | 0.020 |
Why?
| | Ligation | 1 | 2004 | 77 | 0.010 |
Why?
| | Thrombectomy | 1 | 2004 | 53 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 2004 | 175 | 0.010 |
Why?
| | Escherichia coli Infections | 1 | 2004 | 102 | 0.010 |
Why?
| | Adolescent | 2 | 2006 | 17940 | 0.010 |
Why?
| | Hospitalization | 1 | 2012 | 1766 | 0.010 |
Why?
| | Washington | 1 | 2003 | 136 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1598 | 0.010 |
Why?
| | Popliteal Vein | 1 | 2001 | 4 | 0.010 |
Why?
| | Child, Preschool | 1 | 1995 | 9165 | 0.010 |
Why?
| | Hospital Charges | 1 | 2001 | 39 | 0.010 |
Why?
| | Trismus | 1 | 2001 | 2 | 0.010 |
Why?
| | Obesity, Morbid | 1 | 2004 | 199 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1725 | 0.010 |
Why?
| | Cellulitis | 1 | 2001 | 46 | 0.010 |
Why?
| | Radiotherapy Dosage | 1 | 2001 | 246 | 0.010 |
Why?
| | Necrosis | 1 | 2001 | 211 | 0.010 |
Why?
| | Eye Diseases | 1 | 2001 | 76 | 0.010 |
Why?
| | Creatine Kinase | 1 | 2000 | 72 | 0.010 |
Why?
| | Anesthesia, General | 1 | 2000 | 44 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2001 | 334 | 0.010 |
Why?
| | Isoenzymes | 1 | 2000 | 287 | 0.010 |
Why?
| | Rectum | 1 | 2000 | 151 | 0.010 |
Why?
| | Cardiopulmonary Bypass | 1 | 2000 | 176 | 0.010 |
Why?
| | Myocardial Ischemia | 1 | 2000 | 238 | 0.010 |
Why?
| | Blindness | 1 | 1998 | 37 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2001 | 1127 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2001 | 1177 | 0.010 |
Why?
| | Drug Evaluation | 1 | 1997 | 79 | 0.010 |
Why?
| | Electrocardiography | 1 | 2000 | 560 | 0.010 |
Why?
| | Decision Making | 1 | 2003 | 791 | 0.010 |
Why?
| | Diabetes Complications | 1 | 1998 | 212 | 0.010 |
Why?
| | Child | 1 | 1995 | 18539 | 0.010 |
Why?
| | Heparin | 1 | 1997 | 227 | 0.010 |
Why?
| | Algorithms | 1 | 2001 | 1494 | 0.010 |
Why?
| | Hemorrhage | 1 | 1998 | 618 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 1997 | 1359 | 0.010 |
Why?
| | Smoking | 1 | 1998 | 1465 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2000 | 4780 | 0.010 |
Why?
| | Mice | 1 | 2000 | 15087 | 0.000 |
Why?
|
|
Matsumura's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|